PTC THERAPEUTICS ($PTCT) posted quarterly earnings results for Q3 2026 on Thursday, October 29th. The company reported earnings of $0.61 per share, beating estimates of $0.35 by $0.26. The company also reported revenue of $357,810,000, beating estimates of $310,660,890 by $47,149,110.
Stock price change since market close: -6.92%
You can see Quiver Quantitative's $PTCT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PTC THERAPEUTICS Insider Trading Activity
PTC THERAPEUTICS insiders have traded $PTCT stock on the open market 71 times in the past 6 months. Of those trades, 0 have been purchases and 71 have been sales.
Here’s a breakdown of recent trading of $PTCT stock by insiders over the last 6 months:
- NEIL GREGORY ALMSTEAD (CHIEF TECHNICAL OPS OFFICER) has made 0 purchases and 20 sales selling 107,400 shares for an estimated $9,184,850.
- MICHAEL SCHMERTZLER has made 0 purchases and 20 sales selling 95,000 shares for an estimated $6,620,968.
- MARK ELLIOTT BOULDING (EXEC. VP AND CLO) has made 0 purchases and 19 sales selling 23,431 shares for an estimated $1,807,199.
- MATTHEW B. KLEIN (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 5 sales selling 22,864 shares for an estimated $1,622,875.
- ERIC PAUWELS (CHIEF BUSINESS OFFICER) has made 0 purchases and 2 sales selling 21,277 shares for an estimated $1,595,775.
- CHRISTINE MARIE UTTER (SVP, CHIEF ACCOUNTING OFFICER) sold 19,686 shares for an estimated $1,487,474
- MARY L. SMITH has made 0 purchases and 2 sales selling 15,834 shares for an estimated $1,425,060.
- GLENN JR MD PHD STEELE sold 12,000 shares for an estimated $781,920
- PIERRE GRAVIER (CHIEF FINANCIAL OFFICER) sold 3,494 shares for an estimated $280,742
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
PTC THERAPEUTICS Hedge Fund Activity
We have seen 198 institutional investors add shares of PTC THERAPEUTICS stock to their portfolio, and 167 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WESTFIELD CAPITAL MANAGEMENT CO LP added 1,956,156 shares (+inf%) to their portfolio in Q2 2026, for an estimated $159,563,644
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,722,688 shares (+inf%) to their portfolio in Q2 2026, for an estimated $140,519,660
- FULLER & THALER ASSET MANAGEMENT, INC. added 1,156,819 shares (+inf%) to their portfolio in Q2 2026, for an estimated $94,361,725
- UBS GROUP AG removed 1,102,342 shares (-80.8%) from their portfolio in Q2 2026, for an estimated $89,918,036
- BLACKROCK, INC. added 1,015,837 shares (+7.8%) to their portfolio in Q2 2026, for an estimated $82,861,824
- ARMISTICE CAPITAL, LLC removed 1,003,054 shares (-48.4%) from their portfolio in Q2 2026, for an estimated $81,819,114
- TORONTO DOMINION BANK removed 860,117 shares (-28.4%) from their portfolio in Q2 2026, for an estimated $70,159,743
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
PTC THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $PTCT recently. We have seen 5 analysts offer price targets for $PTCT in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $85.0 on 07/07/2026
- Geoff Meacham from Citigroup set a target price of $108.0 on 06/09/2026
- Faisal Khurshid from Jefferies set a target price of $85.0 on 05/27/2026
- Benjamin Burnett from Wells Fargo set a target price of $95.0 on 05/08/2026
- Joseph Thome from TD Cowen set a target price of $90.0 on 05/08/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
